$CELZ

Timothy Warbington, CEO of Creative Medical Technology Holdings (CELZ), disclosed a 13.7% stake in the company's common stock. The investment follows a deal where Creative Acquisition Corp., led by Warbington, received 1 million restricted shares. Warbington plans to hold the shares for investment purposes but may buy or sell more in the future. He has no current plans for board changes or mergers. Warbington also serves as Chairman and CEO of Creative Acquisition Corp.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purcha

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 28, 2026, the stockholders of Creative Medical Technology Holdings, Inc. (the “Company”) approved an amendment to the Company’s Articles of Incorporation to increase the number of author

Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON

Creative Medical Technology Holdings (NASDAQ: CELZ) issued a mid-year update. It said Olastrocel (CELZ-201) has WHO-approved naming and reported positive interim 180-day ADAPT trial results; the FDA cleared an expanded cohort for patients using <90 mg/day morphine equivalents. Ultrasome™ pilot data showed a 93% primary endpoint response. The CELZ-Biodefense Atlas program advanced to nationwide AI-enabled veteran data collection.

Creative Medical Technology Holdings (CELZ) said it secured about $4.5M in gross proceeds via warrant exercises and related stock purchases. The company will exercise warrants for up to 2,790,340 shares and investors will buy 5,580,680 shares at $1.60/share, with new five-year warrants issued. Closing is expected June 30, 2026.

Creative Medical Technology Holdings (Nasdaq: CELZ) said it agreed with warrant holders to immediately exercise existing warrants for up to 2,790,340 shares at a reduced $1.60 exercise price, raising about $4.5M gross proceeds before fees. In return, it will issue new unregistered warrants for up to 5,580,680 shares at $1.60, pending shareholder approval. Closing expected June 30, 2026.

Creative Medical Technology (CELZ) said the FDA cleared an amended protocol to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain. The company will add 15 patients using <90 mg morphine equivalents/day; the new cohort is 85% enrolled and uses its AI pain-medication monitoring. Creative Medical cited positive 180-day interim results and a DSMB report of no significant adverse events, and said it is preparing for Phase 3 discussions.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced regulatory approval for its BioDefense Inc. Burn Pit Initiative, aiming to develop a molecular and cellular database for veterans exposed to toxic burn pits. The initiative will leverage AI and iPSC technology using existing partnerships, without requiring new fundraising, despite the company's recent stock volatility and net loss. The company highlights its strong short-term liquidity with a current ratio of 20.71, as per InvestingPro data.